ArticleFrontiers in oncology2026
Exploring the pharmacological mechanisms of resibufogenin in castration-resistant prostate cancer via network pharmacology and experimental validation.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Resibufogenin (RBG) has shown anti-tumor effects in many cancers, but its role and mechanism in castration-resistant prostate cancer (CRPC) are still unclear. Methods: We screened a library of reactive oxygen species (ROS)-related compounds and selected RBG for further study. We evaluated its anti-proliferative effects in PC3 and RM1 cells by CCK-8 assay, colony formation assay, ROS detection, and Western blot. We explored the possible targets and pathways of RBG in PCa by network pharmacology and clinical data analysis. We then studied the key candidate targets by molecular docking and molecular dynamics (MD) simulation. Results: Among 20 ROS-related compounds, RBG showed the strongest inhibitory effect on PC3 cell viability. Conclusions: This study suggests that RBG inhibits malignant phenotypes of CRPC cells and may exert its anti-tumor effects in part through interaction with BRAF and modulation of the MAPK signaling pathway. These findings support RBG as a promising candidate for further study in prostate cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.